Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cochrane ENT at the Nuffield Department of Surgical Sciences has published two systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell following COVID-19 infection.

Woman smelling the scent from an open bottle

Loss of sense of smell is a frequent symptom following COVID-19 infection. Although for a significant proportion of patients, the loss is only temporary and their sense of smell recovers relatively quickly, for others, the problem can persist and can have a major impact on quality of life.

The Cochrane reviews highlight the current uncertainty about the treatments and the ways to prevent lasting problems with sense of smell after COVID-19 infection.

The first review, 'Interventions for the treatment of persistent smell disorders (olfactory dysfunction) after COVID-19 infection' involved one study with 18 people with problems with their sense of smell that started after a COVID-19 infection and lasted a least four weeks. It compared steroid tablets plus a nasal spray (consisting of a mix of steroids, decongestant and an agent that breaks down mucus) with no treatment.

Researchers at Cochrane ENT identified that the potential benefits and harms of treatments for problems with sense of smell (reduced, changed or lost sense of smell) that last weeks or months after COVID-19 are very uncertain.

The second review, 'Interventions for the prevention of persistent smell disorders (olfactory dysfunction) after COVID-19 infection', involved one study with 100 people with problems with their sense of smell that started after a COVID-19 infection and had lasted less than four weeks at the start of the study. It compared a steroid spray that goes into the nose with no treatment. Everyone taking part in the study was asked to spend a short time each day practising smelling particular scents, to try and stimulate their sense of smell to return. 

The team discovered that the potential benefits and harms of interventions to prevent problems with sense of smell (reduced, changed or lost sense of smell) that last weeks or months after COVID-19 are also very uncertain.

These are living systematic reviews, which will include new evidence as it becomes available. 

 

Similar stories

EndoNET randomises first patient of 2023

A trial investigating how effective endocrine treatment is, prior to surgery in post-menopausal women with breast cancer, has randomised its first patient of the year.

New Cochrane review on antihistamines for motion sickness

A new systematic review from Cochrane ENT at the Nuffield Department of Surgical Sciences says antihistamines are likely to reduce the risk of developing motion sickness (travel sickness) in susceptible adults under naturally occurring conditions of movement, but they may be more likely to cause drowsiness than placebo.

Life-changing results from DRWF Human Islet Isolation Facility at NDS

A new documentary film launched by the Diabetes Research and Wellness Foundation (DRWF) on World Diabetes Day 2022 features an interview with Professor Paul Johnson, as he describes life-changing results from the DRWF Human Islet Isolation Facility at the Nuffield Department of Surgical Sciences (NDS).

Blog posts

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.